Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002136
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase I Trial of Tecogalan Sodium DS-4152 Administered as an Infusion Every 21 Days
Sponsor:
Daiichi Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Trial of Tecogalan Sodium DS-4152 Administered as an Infusion Every 21 Days
Status:
COMPLETED
Status Verified Date:
1996-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety of different doses and dosing regimens of tecogalan sodium DS-4152 and to establish the MTD at each of the different dosing schedules
Detailed Description:
Patients receive intravenous DS-4152 by infusion once every 21 days courses may repeat Patients undergo weekly follow-up A punch biopsy will be obtained from patients with Kaposis sarcoma
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 4152A-PRT001 | None | None | None |